Hematology Medical Billing Services —
Infusion, Blood Disorders & All Heme Codes

Most infused drugs are dosed and billed in milligrams; clotting factor concentrates (Factor VIII, Factor IX, bypassing agents) are dosed and billed in International Units (IU) based on the patient's body weight and target factor activity level. A typical infusion might be 3,000 IU, and the J-code's unit definition is tied to IU, not vials or milligrams. Billing by vial count instead of total IU administered is one of the most common and costly errors in hemophilia billing — factor products are priced high enough per IU that the error can represent tens of thousands of dollars on a single infusion. We calculate units directly from the pharmacy dispensing record and infusion documentation, never from vial count.

The bone marrow procedure itself (aspiration and/or core biopsy, billed under 38221 or 38222) is separate from the pathology interpretation of the specimen. When the hematologist performs the procedure and an outside pathology lab interprets the specimen and bills its own claim, the hematologist bills only the procedure code — adding an interpretation code on top would create a duplicate-service denial once both claims reach the payer. When the hematology practice performs both the procedure and generates its own interpretation report, both are separately billable.

Yes — the chemotherapy administration hierarchy (primary infusion 96413, sequential 96417, concurrent 96368/96367) applies identically whether the regimen is treating lymphoma, leukemia, or a solid tumor. Multi-agent regimens common in heme malignancy treatment generate dense same-day infusion claims, and the correct code for each agent depends entirely on the infusion record's start times and sequencing — billing two primary infusion codes on the same date is an automatic duplicate-service denial regardless of the underlying diagnosis.

Clotting factor concentrates and erythropoiesis-stimulating agents for anemia both carry aggressive step-therapy and documentation requirements from commercial payers, and because these are scheduled, recurring infusions, an authorization that lapses mid-course of treatment is a real risk. We verify authorization before each scheduled infusion and manage the renewal cycle proactively for patients on chronic factor or ESA therapy, rather than waiting for a denial to discover an authorization expired.

Hematologic malignancy trials carry the same billing-separation obligation oncology trials do: routine standard-of-care costs are billable to insurance, while protocol-required items (additional labs, extra imaging, or monitoring visits required only because of the study) must be billed to the trial sponsor. Before enrolling a Medicare or Medicaid patient in an active trial, we build a billing segregation map from the protocol and flag every enrolled patient's claims for review against that map before submission.

Yes. Chronic anticoagulation management — including physician review of remote or home INR monitoring — generates billable work distinct from a standard E&M visit, and practices managing a large anticoagulation population routinely under-bill this ongoing monitoring work because it doesn't happen during a scheduled office visit. We identify patients on chronic anticoagulation therapy and capture the monitoring-based billing separately, rather than letting it fold silently into general E&M coding.

Transfusion of blood or blood components is billed under its own administration code (36430), separate from the product itself and separate from any same-day E&M or infusion services. We apply component-specific coding based on what was actually transfused — packed red cells, platelets, plasma, or cryoprecipitate — and coordinate transfusion billing with any same-day chemotherapy or factor infusion to avoid the administration codes being bundled incorrectly.